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Abstract. Background/Aim: Von Recklinghausen disease is
a syndrome characterized by a wide phenotypic variability
giving rise to both, cutaneous and visceral benign and
malignant neoplasms. The first include cutaneous
neurofibromas, subcutaneous and plexiform neurofibromas.
The latter can undergo malignant transformation and/or
determine elephantiasis neuromatosa. Visceral tumors may
include malignant peripheral nerve sheet tumors,
gastrointestinal stromal tumors, cerebral gliomas and
abdominal neurofibromas. In the present study, the authors
discuss the clinical and biomolecular characterization of a
cohort of 20 families with a diagnosis of type 1
neurofibromatosis. Patients and Methods: Clinically, the
cohort includes three probands with elephantiasis
neuromatosa and a peculiarly high incidence of breast and
gastrointestinal cancer. Results: Among the 14 NF1
mutations documented, 10 encoding for a truncated protein
have been associated to particularly aggressive clinical
phenotypes including elephantiasis neuromatosa, malignant
peripheral nerve sheet tumors, breast cancer, gastrointestinal
stromal tumors. Conclusion: This effect on protein synthesis,
rather than the type of NF1 mutation, is the key to the
explanation of the genotype-phenotype correlations in the
context of neurofibromatosis type 1.
Cutaneous or subcutaneous neurofibromas, plexiform
neurofibromas, axillary or inguinal freckling, optic gliomas,
iris Lisch nodules and multiple café au-lait spots are the
main clinical features of NF1 (Neurofibromatosis type 1),
also called von Recklinghausen disease or peripheral
neurofibromatosis, which is one of the most common
autosomal dominant disorders, with nearly 100% penetrance
by adulthood (1). Skin lesions, termed cutaneous
neurofibromas, derived from skin sensory nerves or single
nerve ending such as dermal tumors associated with large
nerves, may spread within the dermis and appear as a diffuse
mass. Another type of lesion, plexiform neurofibromas
(PNFs), usually involves major nerve trunks or nerve plexi;
sometimes visible on the surface of the body, but it may be
also internal. Lesions visible on the skin surface, may arise
from superficial peripheral nerves or represent the superficial
extension of a deeper massive plexiform mass (2). While
cutaneous neurofibromas are detected in almost all NF1 adult
patients, PNFs are present in 30-50% (1, 3) of NF1 patients;
a fraction of PNF (10-15%) may transform into malignant
peripheral nerve sheet tumors (MPNSTs) (4, 5) and can,
though rarely, determine clinical aspects of hypertrophy or a
clear-cut elephantiasis neuromatosa (EN) (6). It is known
that in the context of NF1 we can find a wide phenotypic
variability, both in the same family and among different
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families. It is, therefore, possible to find patients with few
skin lesions and mild clinical phenotype, along with patients
presenting an aggressive clinical phenotype, including
gastrointestinal stromal tumors (GISTs), brain tumors (low-
and high-grade gliomas), neuroendocrine tumors
(somatostatinomas, pheocromocytomas), haematologic
tumors (leukemias), breast cancer (7-9) underlying the
malignant progression of neurofibromas (5). PNF, when
plexiform and deep, can define cases of hypertrophy and/or
EN involving the trigeminal nerve, the trunk, and upper and
lower extremities (10, 2). In particular, EN is a rare clinical
manifestation enclosed in the NF1 phenotype and derives
from plexiform neurofibromas of deep nerves associated to
hyper-proliferation of the bone and the perineural connective
tissue infiltrating adjacent fat and muscles, containing a
mixture of Schwann cells, fibroblasts, reticulin, collagen
fibers, and a loose mucoid matrix (6). Furthermore
lymphedema, in EN, based on a congenital lymphatic
disorder, determines secondary adipocyte hyperplasia
possibly based on cellular trans-differentiation. In fact, the
lymphostasis due to both primary and secondary
lymphedema determine the fat cell transformation resulting
in hypertrophic adipose tissue and fibrosis (11).
Despite the wide genotypic and phenotypic variability in
the context of NF1, just a few genotype-phenotype
correlations have been reported. It is known that deletions in
NF1 are associated to more aggressive clinical phenotypes
with an earlier onset. NF1 deletions have been found in
association to congenital plexiform neurofibromas and/or
appearing in early childhood (<1 year), characterized by
cranio-facial dysmorphisms, and by a particularly complex
neoplastic spectrum, including solid tumors in various
locations exhibiting a higher risk of malignant transformation
for neurofibromas (12). There have been no studies
investigating on the role of NF1 truncating mutations in NF1
syndrome cases with EN and/or solid neoplasms. In this
study, we have described the clinical and biomolecular
characterization of a family cohort with NF1, with particular
attention to the phenotype of EN and other solid neoplasms.
A secondary aim was the analysis of genotype-phenotype
correlations in the assessment of a prognostic role for NF1
truncating mutations in the pathogenesis of particularly
aggressive NF1 phenotypes.
Patients and Methods
Patients. Between 1999 and 2013, twenty families clinically-
diagnosed with NF1 have been identified in the district of Modena.
Reconstruction of family pedigrees of at least three consecutive
generations, collection of photographic documentation of cutaneous
clinical features of different first, second and third degree relatives,
together with evaluation of phenotypic variability (inter- and intra-
familial) and type. Fourteen of these families have been clinically
and instrumentally followed-up to 15 years.
Germline mutation analysis of NF1 gene. Genomic DNA was
extracted from the peripheral blood of patients with NF1 using the
QIAamp DNA Blood Mini Kit (Qiagen Inc., Valencia, CA, USA),
and stored at –20˚C until use. All of the NF1 exons were amplified
by PCR with intron spanning primers as described by (13, 14) and
analyzed with denaturing high-performance liquid chromatography
(DHPLC), as described elsewhere (15). For each abnormal elution
profile, genomic DNA was directly sequenced in both directions
using a CEQ Dye-Terminator Cycle Sequencing Kit (Beckman
Coulter Inc., Miami, FL, USA) according to the manufacturer’s
protocol. Mutations were checked using the Mutalyzer program
(https://mutalyzer.nl/). 
Results
Clinical characterization. Twenty patients were clinically
diagnosed with NF1; 14 of them carried an NF1 germline
mutation (8 females and 6 males; mean age=52, 07;
range=29-73 years). The tumor spectrum in the NF1
probands included colonic and duodenal adenomatous
polyps, two colonic adenocarcinomas, two GISTs, three
breast tumors and cerebral glioblastomas. Among affected
first-degree relatives, adenomatous polyps, cerebral
glioblastoma, colon cancers, breast cancers, pancreatic
cancer and kidney cancers were detected. In particular,
duodenum cancers (GIST and adenomatous polyps) were
diagnosed in four probands, kidney tumors in five first-
degree relatives, breast cancer in four first degree relatives
and pancreatic cancer in two first degree relatives (Table I).
Three probands showed EN and a peculiarly high incidence
of breast and gastrointestinal cancer.
Our first patient was a Caucasian female with a case of
giant elephantiasis of the arm and numerous cutaneous
neurofibromas, some of them pedunculated and of major
dimension. The family history highlighted familial
segregation with generational anticipation of NF1 phenotype
(Figures 1 and 2). The proband underwent surgical
enucleation of an arm tumor. Pathology revealed at gross
examination a skin flap of 30×10 cm with 4 nodular lesions,
respectively of 5, 9, 10 and 11 cm of diameter. The minor
lesion was a dermal pedunculated nodule protruding from the
skin, while the other three lesions were deeper and
subcutaneous. Microscopically all the nodules were
composed by small spindle cells with indistinct cell borders,
scanty pale cytoplasm and elongated nuclei with a serpentine
configuration and pointed ends set in a collagenous stroma.
Inflammatory cells, particular mast cells, and small nerve
fibres were also present (Figure 3). Positive staining for S-
100 protein and CD-34 positivity were also observed. The
diagnosis was of multiple neurofibromas. Genetic analysis
detected the germline mutation g.116321C>T; c.1318C>T. 
Our second patient was a female patient brought to our
attention because of a 29-year history of several
neurofibromas and multiple cafè-au-lait macules. The patient
presented giant elephantiasis of the right leg, which started to
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Table I. Clinical and biomolecular features of patients with NF1 syndrome in the district of Modena.
Patient no. Gender Germline Clinical NFs and Tumors in the 
(age in years) mutation features family (age in years)
1. F (61) g.116321C>T; EN, NFs (face, trunk, abdomen), Grandfather: NFs;
c.1318C>T; p.(Arg440*) >6 CAL, molluscus fibrosum Father: >6 CAL, NFs;
Son: >6 CAL, NFs;
Nephew: >6 CAL
2. F (29) g.129042_129043delAG; EN, NFs (abdomen, trunk, giant L4), 
c.1541_1542del; >6 CAL, two central nervous system 
p.(Gln514Argfs*43) hamartomas of the pallidus nucleous, 
mild lombo-sacral meningocele, scoliosis
Father M (56) g.129042_129043delAG; NFs (trunk), >6 CAL, 
c.1541_1542del; macrocephaly, hypertelorism
p.(Gln514Argfs*43)
3. M (36) Exon 20 NFs (abdomen, limbs, face), >6 CAL, Mother: NFs;
c.3457_3460delCTCA axillary freckling, oligophrenia, Daughter: NFs;
p.(Leu1153Metfs*4) EN and plexiform neurofibroma of Aunt: Larynx (68);
the forehead, hearing loss, Cousin: Pancreas (53)
orbito-sphenoid dysplasia
Mother F (73) Exon 20 NFs (abdomen, limbs, face) 
c.3457_3460delCTCA >6 CAL, axillary freckling
p.(Leu1153Metfs*4)
4. F (55) g.139878del; c.2870del; NFs (trunk, face), Mother: NFs
p.(Asn957Ilefs*5) >6 CAL, breast cancer Cousins: Breast Cancer (34, 44)
5. M (71) Exon 20 NFs (trunk, face), >6 CAL, Mother: renal cell carcinoma (75);
Del c.3457-3460delCTCA adenocarcinoma of the Brother: renal cell carcinoma (60)
p.(Leu1153Metfs*4) rectum, GIST, axillary freckling
6. M (56) Exon 6 NFs (trunk), >6 CAL, axillary Brothers: NFs, lung (70);
c.750delT and inguinal freckling, plexiform Son: NFs;
p.(Phe250Leufs*31) neurofibroma of the scalp, Mother: NFs;
Lisch nodules, squamocellular carcinoma of thyroid with Uncles: NFs;
linphonodes and soft Aunt: NFs
tissue metastases
7. F (58) c.2094-2095delCT NFs (face, trunk, tail Son: NFs, >6 CAL, 
of pancreas), adrenal adenoma, lipomas, glioblastoma 
duodenal polyps multiforme (26);
Son: NFs, > 6 CAL
8 F (40) c.3916 C>T NFs, > 6 CAL, breast cancer Daughter: >3 CAL;
Grandfather: NFs
9 M (47) Exon 4 NFs (trunk, face), >6 CAL, Mother: breast cancer (59)
c.479 G >C Lisch nodules, seminoma, 
p.(Arg160Thr) adrenal adenoma
10. M (50) Exon 6: large deletion NFs (face, chest, scalp), >6 CAL, Mother: NFs, colon (70);
axillary and inguinal freckling, GIST, Brother: colon (59);
adenocarcinoma of the colon Uncle: NET (72);
Aunt: lung (52)
11 F (33) Intron 46, c.8051-70A>T NFs (trunk, limbs), >6 CAL, Aunt: lung (72)
optic glioma axillary freckling 
12 F (64) Exon 20 NFs (trunk, limbs, face), >3 CAL, Son: glioblastoma multiforme (30);
c.2093_2094delCT axillary and inguinal freckling, Son: NFs, >3 CAL
p.(Pro698Argfs*3) Breast cancer, multiple lipomas, 
adrenal adenoma, hepatic hemangioma, 
inflammatory polyps of the colon
EN: Elephantiasis neuromatosa; NFs: neurofibromas; CAL: cafè-au-lait spots; GIST: duodenal gastrointestinal stromal tumors; NET: neuroendocrine tumor.
grow during late childhood, and accelerated its expansion in
the following years (Figure 4). At birth she showed a cafè-
au-lait macule on the right thigh. By age 1, she developed a
semi-liquid mass at the same site with the aspects of a
lymphangioma. Lymphedema of the ipsilateral foot and
discrepant leg lengths were noted successively. In the
following years, the leg growth was associated to bone
proliferation, which required many osteotomies aimed to
stop the growth. Two CNS hamartomas of the nucleous
pallidus were also identified by MRI. Personal history and
3D-CT revealed a small lombo-sacral meningocele, a giant
L4 neurofibroma and significant scoliosis. Her family history
was suggestive for NF-1 since her father had macrocephaly,
hypertelorism and multiple cafè-au-lait macules and
neurofibromas. NF1 germline deletion g.129042_129043
delAG; c.1541_1542del; p.(Gln514Argfs*43) was found
both, in the proband and her father. 
Patient number 3 was a 36-year-old patient, presenting at
birth with giant elephantiasis and plexiform neurofibromas
of the forehead, partially covering the left eye. Surgical
correction of such a lesion (Figure 5) allowed the patient to
partly recover the function of the injured eye. The same
patient had also multiple NFs of the abdomen, limbs and
face, more than six CALs, oligophrenia, orbital and sphenoid
dysplasia and hearing loss. At the age of 36, he underwent
surgical amputation of the left leg due to the diagnosis of
malignant neurofibromas. His mother and sister had also NFs
and CALs; the mother carried the same mutation as the
proband, with a truncating effect on protein Exon 20
c.3457_3460delCTCA p.(Leu1153Metfs*4) (Table I).
NF1 gene mutation analysis. The identified constitutional
NF1 gene mutations ranged from single base pair
substitutions to gross deletions and microdelesions appeared
to be uniformly distributed across the gene. In detail, among
the 14 NF1 mutations, 8 (57,1%) were deletions and 10
(71,4%) led to a truncating effect on the protein (Table I).
Two identical mutations (c.3457_3460delCTCA) in exon 20
were associated to different clinical features in two NF1
families unrelated, but with common proclivity to multiple
tumors arising in the same patient and with a higher tumor
burden per family.
Truncating mutations were mainly distributed among the
probands with familial history of NF1 and complex
neoplastic spectrum, including, in particular, breast cancer,
while just one case appeared as first mutation. Moreover,
such mutations with truncating effect were associated to
particularly aggressive phenotypes and characterized by
generational anticipation for both onset age and
aggressiveness of phenotype (probands 1, 2, 3 and 8 of Table
I). Three of the above mentioned probands with truncating
mutations presented with EN; one case had EN of the arm
(patient 1 in Table I) (Figure 2), the second of the lower limb
(patient 2 of Table I) (Figure 4), and the third of EN-like
lesions constituted by pachydermoceles of the frontal and
ocular region (patient 3 of Table II) (Figure 5).
Discussion
Clinical and biomolecular characterization of the family
cohort with NF1 diagnosis discussed here showed, along
with a wide phenotypic variability, a non-negligible role for
EN and other neoplastic manifestations, showing a specific
association between these severe clinical cases and
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Figure 2. Clinical features of NF1 proband (proband 1) with EN of the
arm.
Figure 1. Family pedigree and clinical features of NF1 proband
(proband 1) with EN of the arm cosegregating NF1 germline mutation
g.116321C>T; c.1318C>T.
truncating mutations of NF1. Less than 50 EN cases are
described in the scientific literature; in the majority of the
cases genetic characterization was not performed. The first
question concerns whether the real incidence of this clinical
phenotype could be underestimated. Among the cases
already considered, there are no significant differences
concerning gender, in most cases, however, they are
segregated following the maternal part of the family. In a
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Figure 4. Clinical aspect of Elephantiasis Neuromatosa of the leg
(proband 2).
Figure 5. Clinical aspect of plexiform neurofibroma of the head after
the partial surgical resection (proband 3).
Figure 3. Representative histological images (H&E) of neurofibromatous
lesions involving in the elephantiasis neuromatosa of the arm of
proband 1. 
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Table II. Elephantiasis neuromatosa as clinical manifestation enclosed in the NF1 phenotype. 
Gender - Age/ Family history Proband affected regions Reference
Age of onset and clinical features
M - 20 years/ Grandmother (2000 minute cutaneous Gross elephantiasis neuromatosa Spittel RL and 
At birth tumours and scattered subcutaneous of the left limb. Fernando SE, 1929.
swellings), mother (achondroplasia). Subcutaneous tumors scattered all 
over the body; a pachidermatocele 
of the occipital scalp; cutaneous freckles. 
Bone development increasing.
M - 40 years/ Mother affected by type I Elephantiasis neuromatosa of the neck. Westcott RJ and 
At birth neurofibromatosis. Deformity of the left clavicle, left Ackerman LV, 1947.
leg and cervical column.
M - 22 years/ There was no particular familial Elephantiasis neuromatosa of 
Childhood history of neurofibromatosis. extensively involved the 
chest wall and the axilla.
F - 42 years/ No family history for the Soft irregular bluish end mottled Lenson N, 1956.
- type I neurofibromatosis. mass involving the distal two-thirds of 
the right lower extremity.
M - 16 years/ Not reported. Elephantiasis neuromatosa of the penis. Fethiere W, Carter HW
Childbirth Syringomyelia associated with a cervical and Sturim HS, 1974.
ependymoma. Facial paralysis on the left 
side and paralysis of the left eye muscle. 
Multiple schwannomas involving some cranial nerves. 
M - 11 years/ Not reported. Two cases of elephantiasis neuromatosa respectively Yaghmai I and 
3 years of the left thigh and right leg, overgrowth of Tafazoli M, 1977.
abnormal bones with subperiosteal haemorrhage. 
F - 9 years/ Not reported. Subsequent rapid ossification resulted in 
2 years residual diaphyseal widening after minor trauma.
M - 4 years/ Eleven of his relatives Elephantiasis neuromatosa involving Sty JR, Starshak RJ 
- have neurofibromatosis. the right lower extremity. Numerous cafè-au-lait and Woods GA, 1981.
spots on the lower abdomen and groin.
F - 18 years/ No family history for the Only one large cafè-au-lait spots 
At birth type I neurofibromatosis. on the right hallux. Soft tissue hypertrophy Harris WC Jr, Alpert WJ 
with massive enlargement of both and Marcinko DE, 1982.
proximal and distal phalanges.
F - 17 years/ There was no predisposition to Elephantiasis neuromatosa of the right Holck S, Medgyesi S, 
Childhood either familial or hereditary disorders. gluteal sulcus, coexistent with lipomatosis. Darre E and 
Absence of skeletal lesion. Lassen M, 1984.
F - 30 years/ Not reported. Elephantiasis neuromatosa of the left lower Birch PD and 
At birth limb maximal in the calf. Dysplastic Davies AM, 1988.
bones of the left hemipelvis and leg.
F - 52 years/ The patient denied any manifestations Symmetric elephantiasis neuromatosa Hertzanu Y, Hirsch M, 
Childhood of neurofibro-matosis in her family. of the trunk. Hypovolemic shock Peiser J and 
at the age of 32 years. Avinoach I, 1989.
M - Few months/ No family history of congenital Buphthalmos and regional gigantism with Bardelli AM and 
At birth glaucoma or buphthalmos. evolution in neurofibromatous elephantiasis. Hadjistilianou T, 1989.
A swelling of the right upper lid and 
preauricular region. Hypertrophy of the
soft periorbital tissues. Corneal diameter 
13 mm, rubeosis iridis, ectropion uveae, 
M - 13 months/ Not reported. increased optic nerve cupping.
At birth Buphthalmos, an enlarged optic canal, a 
fibrous dysplasia of the greater wing of s
phenoid bone. Longer right fibula and a 
F - 11 years/ Not reported. slight deformity of the vertebrae of the lumbal tract.
At birth Facial elephantiasis without buphthalmos. 
Greater wing of sphenoid bone; right optic 
foramen larger than the left. Iris nodules, 
ectropion uveae, increased optic nerve cupping. Small 
neurofibromas of the zygomatic and temporal region.
Table II. Continued
great majority the clinical expression was congenital, since
it was diagnosed at birth or during the first decade of life
(Table II). From the clinical definition and pathogenesis of
plexiform neurofibromas point of view, the overgrowth of
connective tissue may be limited to a single superficial nerve
or plexus; when the spread is limited to epithelial tissues,
clinical appearance consists of soft fibrous tumors, named
molluscum fibrosum or pachidermocele (as in our patient 3),
likely histologically corresponding to mixoglioma
gelatiniforme, a plexiform neurofibroma variant lacking
muscle and Schwann cells, not associated to an increase in
the bony development (16, 17). The term EN, referring to the
cutaneous-confined phenotype, might be inappropriate, since
a distinct superficial dysplastic skin alterations known as
Ponti et al: NF1 Truncating Mutations and Aggressive Clinical Phenotype
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Table II. Continued
Gender - Age/ Family history Proband affected regions Reference
Age of onset and clinical features
F - 34 years/ His mother, grandmother, Elephantiasis neuromatosa involving the right Kuo LA and 
Since 8 years sister, nephews had neurofibromatosis. lower limb and pelvis, leading to a right hip Kuo RS, 1990.
disarticulation. Large neurofibroma of the sciatic nerve.
F - 22 years/ No family history for the Enlargement, overgrowth and elongation Roy SM and 
At birth type I neurofibromatosis. of all the bones of right the foot. Ghosh AK, 1992.
M - 21 years/ No cases reported in this family. Gigantism and elongation of all 
At birth the bones of the right foot.
M - 18 years/ His father had elephantiasis Gigantism and elongation of all 
Childhood neuromatosa. the bones of the right foot.
M - 6 years/ No family history for the Enlargement mainly of the forefoot and the swelling 
At birth type I neurofibromatosis. was more prominent between the great and 2nd toe.
M - 3 months/ Family history did not reveal Congenital plexiform neurofibroma Kokandkar HR, 
At birth occurrence of similar illness involving neck with elephantiasis Vyas AS, 
in any of members.neuromatosa with Kumbhakarna NR 
sarcomatous nodule. The skin covering the tumor and Totala RJ, 1994.
was hairy, redundant and dark.
F - 33 years/ Family history of Elephantiasis neuromatosa of the right leg. Münte TF, Matzke 
6 years neurofibro-matosis. Severe dysaesthesia in the right lower leg M, Johannes S, Dietrich B 
not confined to a single nerve. and Dengler R, 1996.
M - 43 years/ Not reported. Gross elephantiasis neuromatosa of the left leg. Stevens KJ, Ludman CN, 
Childhood Large synovial cyst arising from the synovium Sully L and 
of the patello-femoral joint. Preston BJ, 1998.
M - 20 years/ No family history for the Elephantiasis neuromatosa with Becker’s Akyol M, Ozçelik S, 
6 years old type I neurofibromatosis. melanosis. Hairly and brown-black hyperpigmented Marufihah M and 
patches on left shoulder, left upper Elagöz S, 1999.
back and left arm. Lisch nodules.
M - 35 years/ Not reported. Elephantiasis neuromatosa of the right Lorberboym M, 
- thigh and sacral region. A soft tissue mass Trejo L and 
and enlargement of the right upper leg. Lampl Y, 2000.
F - 13 years/ Her mother had type I Elephantiasis of the left leg with recurrent Steenbrugge F, Poffyn B, 
At birth neurofibromatosis. massive subperiosteal haematoma. Uyttendaele D et al., 2001.
F - 41 years/ Not reported. Elephantiasis neuromatosa of the right leg. Hourani R, Rizk T, 
Childhood Optic chiasm glioma. Right tibia and fibula Kung S and 
marrow and cortices hypertrophy. Boudghène F, 2006.
F - 14 years/ Not reported. Elephantiasis neuromatosa involving Martínez-García S, 
At birth the right lower limb. Vera-Casaño A, 
Anaemia and hepatitis B. Eloy-García 
Carrasco C et al., 2008.
M - 56 years/ There was no particular familial A huge mass of elephantiasis Hoshi M, Ieguchi M, 
Childhood history of neurofibromatosis. neuromatosa in the right leg. Taguchi S and 
Yamasaki S, 2009.
M - 15 years/ No family history for the type I Elephantiasis neuromatosa of the right Bano S, Prasad A, 
Childhood neurofibromatosis in leg. Osseous abnormalities included Yadav SN 
first-degree relatives. thinning of bones, erosion of distal et al., 2010.
articular surfaces and periosteal dysplasia.
M: Male; F: female.
pachidermocele or dermatholysis, histologically corresponding
to a gelatiniform mixed glioma, must be distinguished from
EN in patients affected by NF1. Our data show that a
hyperproliferative process involving the soft tissues, bones
and lymphatic system beyond the peri-neural connective can
be responsible of EN in NF1. The lymphostasis and the
following lymphedema trigger an adipocyte metaplasia
whereas the chronic hyperemia produces bone hypertrophy.
Lymphoscyintigraphy and MRI can be an efficacious tool in
the diagnosis and clinical characterization of early onset
cutaneous, subcutaneous and skeletal anomalies, allowing for
detection of details that would not be visible with traditional
radiograms and enabling an in-depth anatomical study
together with a pre-operative assessment. In fact, an
appropriate clinical and instrumental management, including
the evaluation of the functionality of the vascular and
lymphatic system, is critical for classifying EN in its
complex pathogenesis and in the selection of those cases,
that have to be surgically treated with liposculpture and/or
surgical enucleation of neurofibromas. Timing and approach
type, based on specific NF1 mutations predictive of clinical
aggressiveness, might be organized and modulated. However,
it is already well-known that the effective number of
genotype-phenotype correlations is exceedingly low;
however, one of them is related to the role of large NF1
deletions. Truncating mutations produce a stop-codon which
generate a short protein with a reduced function. From a
clinical point of view, the molecular diagnosis of a large NF1
deletion is important because it is frequently associated with
severe clinical manifestations including an increased risk of
MPNSTs as compared with the general NF1 population (18-
20). It is widely assumed that genotype-phenotype
correlations in patients with large NF1 deletions are likely to
be influenced by both the number and type of deleted genes.
Concerning NF1-associated neoplasms, NF1 patients are
at increased risk of several types of neoplasia (7, 21, 22).
There are data suggesting an increased risk of different
malignancies, including breast cancer and leukaemia, among
patients with NF1 (23, 24). Sharif et al. (24) reported an
increased risk of breast cancer among female patients with
NF1. The authors analyzed a British case series of 304
females with NF1, and found that women with NF1 had a 5-
fold increased risk of being diagnosed with breast cancer,
being the most common type of breast cancer an infiltrating
ductal carcinoma. In particular, the increased risk appeared
to be specific to women under 50 years of age. Similarly,
Seminog et al. (25) reported a three-fold risk for breast
cancer in women under 50 years with NF1. A different study
that looked at mortality in NF1, found that women with NF1
were 3.5-times more likely to die from breast cancer than
women in the general population (PMR=3.5; 95%CI 1.3–7.7)
(9). There have been numerous case reports of patients with
NF1 who presented ductal type breast carcinomas, including
a male patient who was diagnosed with bilateral ductal
carcinoma at age 18 (26).
We reported an equally high risk of breast cancer among
NF1 female gene-carriers and their family members, and
agree on the opportunity of offering a screening program that
includes early and annual clinical and radiographic screening
for breast cancer in those patients with clinical and
biomolecular diagnosis of NF1 (27). 
Although the phenomenon of generational anticipation of
NF1 syndrome was not previously discussed in the scientific
literature, this feature is certainly present in our experience,
both in families and probands with EN carrying NF1
germline mutation, as well as in those without EN. In
particular, as in the case discussed above (Figure 1), the
anticipation phenomenon regarded both, aggressiveness and
onset age of the cutaneous phenotype. Recent evidence has
shed light on the role of modifier genes and of environmental
factors in the pathogenesis of intra- and inter- familial
phenotypic variability. It clearly appears that the clinical
expression of NF1 tends to be similar in close relatives and
will decrease with the degree of relatedness (28). In
particular, studies on homozygote twins showed that genetic
factors determined the onset of particular phenotypic features
and in one case, twins with markedly different NF1
phenotype (only one with NF1 features) carried a post-
zygotic NF1 gene mutation, identified in the affected twin
who presented a somatic NF1 mosaicism (29). It is possible
that, similarly to other genetic diseases, NF1 can be affected
by the accumulation of progressive mutations that, in case of
familial segregation, can determine an anticipation of onset
age and an increased aggressiveness of the phenotype
throughout the generations.
Concerning potential modifier genes, it is known that an
early reduction in mismatch repair capacity can lead to an
accumulation of second hits in NF1; so it is possible to
hypothesize that overlapping molecular pathways might
underlie a greater susceptibility to the acquisition of second
mutations, both germline and somatic, that are responsible
for phenotypic characterization. 
Previous studies (30) were not able to find any clear
relationships between a NF1 mutation and distinct clinical
features and some authors hypothesized that the phenotypic
differences in NF1 patients are more likely to be caused by
mechanisms such as a second hit, modifying genes and
stochastic events (31).
While discussing the somatic mutational spectrum of NF1
associated tumors Laycock-van Spyk et al. (32) reported that
about 75% (191/254) of the somatic mutations associated
with NF1 tumors comprise mutations that are predicted to
give rise to truncated proteins and 173 of these truncations
arise form deletion, nonsense mutation or frameshift events.
In particular, the authors highlighted that the high proportion
of truncating mutations were involved in the somatic
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inactivation of the NF1 gene in cutaneous neurofibromas. An
Italian study on constitutional NF1 mutations by De Luca et
al. reported 61 out of 75 (81%) truncating mutations (33).
Biomolecular evidence regarding PNFs associated to EN
and/or MPNST suggest an equally critical role of NF1
germline aberrations, leading to the truncating protein
effect. The biomolecular study confirmed a pathogenetic
role for big deletions in the genesis of particularly
aggressive and complex clinical phenotypes, highlighting an
association between NF1 truncating mutations and EN,
MPNST and NF1-associated malignancies. Future
biomolecular studies shall be based not only on the analysis
of NF1 mutation types, but also on their direct effect on the
protein synthesis, and on a wider case series including
patients with EN- and other NF1-associated tumors.
Therefore, it will be possible to clarify the possible
phenotypic correlations of NF1 germline mutations with
truncating effect and their potential consequences in terms
of screening and follow-up planning.
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